Anti-Trop-2 ADC drug Trodelvy combined with PD-L1 monoantitic Tecentriq: Treatment of urethral derilopathy and non-small cell lung cancer.
-
Last Update: 2020-07-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The !---- leading biopharmaceutical company in the field of antibody drug coupling (ADC) has announced a partnership with Roche to assess the potential of Thetreves, Immunomedic's anti-Trop-2 ADC drug, and Roche's PD-L1 monoanti-Tecentriq joint treatment of metastatic ural path skin cancer (mUC) and metastatic non-small cell lung cancer (mNSCLC)Trodelvy is the first FDA-approved ADC drug to be used to treat patients with metastatic triple-negative breast cancer, and the first FDA-approved ADC drug to target human-nourishing layer cell surface antigen 2 (Trop-2)Image Caption: "Trodelvy can cause tumor cell death and release new antigens, which can be co-produced with immunocheckpoint inhibitors such as Tecentriq, which may create synergies."" Under the cooperation agreement, Roche will use its MORPHEUS platform for two open-label, multi-center, and random 1b/2 studiesMORPHEUS-mUC study will randomly select mUC patients who have not received CPI treatment and failed after platinum chemotherapy to receive joint treatment with Tecentriq and Trodelvy, or only Tecentriqsecond study, Morpheus-Lung, will recruit mNSCLC patients who have received CPI treatment, which is treated only by Tecentriq and Trodelvy, or Dositatha.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
